Compelling preclinical evidence demonstrates that by inhibiting TGF‐β signalling, losartan can potently remodel the TME, reducing ECM stiffness and collagen deposition while promoting tumour vascular normalisation; these changes can synergistically enhance perfusion and the intratumoral penetration of conventional chemotherapeutics [13, 18]. This evidence concerns the gene TGFB1 and neoplasm.